HF  RTW Investments


     Office Locations:

40 10th Avenue, Floor 7
New York, NY 10014
Phone: 646-597-6980
Fax: 646-597-6998



  • Early
  • Growth



  • Life Sciences & Healthcare



    RTW Investments is an investment firm focused on investments in the biopharma space, primarily within gene therapy, oligos, cancer, and rare disease. Investments are made anywhere across a company's life cycle from pre-clinical to commercial stage assets. RTW invests across the capital structure and invests in both public and private companies.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or New York Database subscription.
    Alexandra Taracanova PhD Director of Investor Relations
    Alice Lee JD Chief Compliance Officer and Senior Counsel
    Brad Sitko Managing Director
    David Moore Controller
    Gotham Makker MD Head of Strategic Investments


    Recent Funding Events (trailing 12 months):










      Series D


      Umoja Biopharma



      Series B


      Pyxis Oncology



      Series B


      Monte Rosa Therapeutics



      Series C


      Artiva Biotherapeutics



      Series B


      Tenaya Therapeutics



      Series C


    Portfolio companies include:


    Recent News: